摘要
目的观察阿帕替尼在甲胎蛋白(AFP)阳性晚期胃癌中的疗效和安全性。方法收集本院2009年9月至2017年1月的AFP阳性胃癌患者7例,均接受阿帕替尼,联合或不联合全身化疗,阿帕替尼具体剂量为250~850 mg/d。分别采用RECIST 1.1版与NCI CTC 4.0版标准评价近期疗效和不良反应。采用Kaplan-Meier法进行生存分析。结果 7例患者均可评价疗效和安全性,获PR 1例、SD 3例和PD 3例,有效率为14.3%,疾病控制率为57.1%。中位无进展生存期为4个月(95%CI:0~9.1个月),中位总生存期为7个月(95%CI:5.7~8.3个月)。7例患者中AFP下降5例。主要不良反应包括高血压、蛋白尿、血小板减少及粒细胞减少等,主要为1~3级。除1例出现3级高血压停止用药外,其他患者的不良反应可控,耐受性良好。结论阿帕替尼治疗AFP阳性晚期胃癌疗效显著,不良反应可控、耐受性良好。
Objective To evaluate the efficacy and safety of apatinib in advanced alpha fetoprotein （AFP）-positive gastric cancer. Methods Seven patients with advanced AFP-positive gastric cancer from September 2009 to January 2017 received apatinib were enrolled. All the patients were given apatinib alone or in combination with chemotherapy, and the dose of apatinib was 250-850 mg/d. The efficacy and safety were evaluated by RECIST criteria （version 1. 1 ） and NCI CTC 4. 0 criteria. Overall survival （OS） and progression-free survival （PFS） were analyzed by Kaplan-Meier method. Results All patients were available for evaluation. Among the 7 patients, 1 case got partial respond and 3 cases had stable disease. The response rate was 14. 3% and disease control rate was 57.1%. The median PFS was 4. 0 months （95%C1： 0-9.1） and the median OS was 7.0 months （95%CI： 5.7-8. 3）. Among the 7 pa- tients, the APF level decreased in 5 cases. The common treatment-related side effects included hypertension, protcinuria, thrombocyto- penia and nentropenia, mainly in grade 1-3. Except one patient discontinued apatinib treatment due to grade 3 hypertension, the side effects were controlled and tolerated well in the other patients. Conclusion Apatinib is effective and tolerable in advanced AFP-posi- tire gastric cancer.
出处
《临床肿瘤学杂志》
CAS
2017年第10期924-928,共5页
Chinese Clinical Oncology
